Translating Asian‐Dominant Pivotal Evidence Into EU Marketing Authorization: An EMA Regulatory Document Analysis, 2021–2025

ABSTRACT

An increasing number of novel molecular entities and biosimilars reach the European Medicines Agency (EMA) supported by pivotal evidence derived predominantly from Asian patient populations. This creates regulatory challenges that the existing ICH E5 framework was not originally designed to address. We performed a retrospective regulatory document analysis of 10 EMA applications assessed between 2021 and 2025 in which pivotal evidence was predominantly Asian. European Public Assessment Reports were reviewed for bridging strategy, intrinsic ethnic sensitivity, data‐integrity findings, clinical‐practice comparability, and regulatory outcome. Eight applications were authorized and two were withdrawn. Reflecting the eligible EMA case set during 2021–2025, the included products were concentrated in oncology, particularly PD‐1/PD‐L1 monoclonal antibodies. EMA decisions were shaped by four recurring considerations: expected intrinsic ethnic sensitivity, adequacy of bridging evidence, Good Clinical Practice or manufacturing findings, and comparability of Chinese clinical practice with EU standard of care. Clinical practice divergence was the least standardized source of residual uncertainty. Asian‐dominant evidence can support EU authorization, but transparent assessment of extrinsic practice differences is essential for reliable translation.